|
US5925362A
(en)
*
|
1993-08-11 |
1999-07-20 |
Jenner Technologies |
Method to elicit an antitumor response with human prostate-specific antigen
|
|
US20010036928A1
(en)
*
|
1996-04-22 |
2001-11-01 |
Chamberlain Ronald S. |
Heterologous boosting immunizations
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CN1298851C
(zh)
*
|
1998-11-18 |
2007-02-07 |
牛津生物医学（英国）有限公司 |
多肽
|
|
US7148035B1
(en)
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
JP4409097B2
(ja)
*
|
1998-12-09 |
2010-02-03 |
アメリカ合衆国 |
複数の共刺激分子を発現する組換えベクターおよびその利用
|
|
EP1865065A1
(en)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
ATE369895T1
(de)
*
|
2002-04-09 |
2007-09-15 |
Sanofi Pasteur Ltd |
Modifizierte cea nucleinsäure und expressionsvektoren
|
|
AU2004267117B2
(en)
*
|
2003-08-21 |
2011-01-20 |
Virax Development Pty Ltd |
Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
|
|
US8562970B2
(en)
*
|
2003-10-08 |
2013-10-22 |
Sanofi Pasteur Limited |
Modified CEA/B7 vector
|
|
WO2005046614A2
(en)
*
|
2003-11-12 |
2005-05-26 |
Therion Biologics Corporation |
System for treating and preventing breast cancer
|
|
US8901093B2
(en)
|
2003-11-12 |
2014-12-02 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Custom vectors for treating and preventing pancreatic cancer
|
|
MX2011007494A
(es)
|
2009-01-13 |
2011-08-12 |
Transgene Sa |
Uso de una fraccion de la mitocondria de acidos nucleicos de saccharomyces cerevisiae para la estimulacion inmune.
|
|
MX2011007386A
(es)
|
2009-01-20 |
2011-08-03 |
Transgene Sa |
Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
|
|
WO2010108908A1
(en)
|
2009-03-24 |
2010-09-30 |
Transgene Sa |
Biomarker for monitoring patients
|
|
JP5661738B2
(ja)
|
2009-04-17 |
2015-01-28 |
トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． |
患者をモニターするためのバイオマーカー
|
|
CA2767458A1
(en)
|
2009-07-10 |
2011-01-13 |
Bruce Acres |
Biomarker for selecting patients and related methods
|
|
WO2012019125A2
(en)
|
2010-08-06 |
2012-02-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for prostate cancer and methods for their detection
|
|
US9725494B2
(en)
*
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
|
CA2928199C
(en)
*
|
2013-11-05 |
2025-06-17 |
Bavarian Nordic A/S |
POLYTHERAPY FOR CANCER TREATMENT USING A POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST AND/OR AGONIST OF AN IMMUNE CHECKPOINT INHIBITOR
|
|
CA2946606C
(en)
|
2014-05-13 |
2023-06-06 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3
|
|
US10765710B2
(en)
|
2014-07-16 |
2020-09-08 |
Institut Gustave-Roussy |
Combination of oncolytic virus with immune checkpoint modulators
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
US11753652B2
(en)
|
2015-07-31 |
2023-09-12 |
Bavarian Nordic A/S |
Cassette encoding a FPV/brachyury fusion protein
|
|
EP3400009A2
(en)
|
2016-01-05 |
2018-11-14 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
WO2017129769A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
EP3452081A1
(en)
|
2016-05-04 |
2019-03-13 |
Transgene SA |
Combination therapy with cpg tlr9 ligand
|
|
EP3518964A2
(en)
|
2016-09-28 |
2019-08-07 |
Bavarian Nordic A/S |
Compositions and methods for enhancing the stability of transgenes in poxviruses
|
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
EP3562946B1
(en)
|
2016-12-28 |
2021-11-24 |
Transgene SA |
Oncolytic viruses and therapeutic molecules
|
|
KR102808275B1
(ko)
|
2017-04-14 |
2025-05-20 |
탈락 테라퓨틱스, 인크. |
면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
|
|
US11052147B2
(en)
|
2017-05-15 |
2021-07-06 |
Janssen Vaccines & Prevention B.V. |
Stable virus-containing composition
|
|
CA3061678A1
(en)
|
2017-05-15 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Stable virus-containing composition
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
JP7202362B2
(ja)
|
2017-08-24 |
2023-01-11 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
|
|
WO2019170820A1
(en)
|
2018-03-07 |
2019-09-12 |
Transgene |
Parapoxvirus vectors
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
EP3847246A1
(en)
|
2018-09-06 |
2021-07-14 |
Bavarian Nordic A/S |
Storage improved poxvirus compositions
|
|
EP3976071A1
(en)
|
2019-05-29 |
2022-04-06 |
Université de Tours |
Toxoplasma platform for treating cancer
|
|
US11920136B2
(en)
|
2020-02-28 |
2024-03-05 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
|
WO2021180943A1
(en)
|
2020-03-12 |
2021-09-16 |
Bavarian Nordic A/S |
Compositions improving poxvirus stability
|
|
WO2024038175A1
(en)
|
2022-08-18 |
2024-02-22 |
Transgene |
Chimeric poxviruses
|
|
WO2026041811A1
(en)
|
2024-08-23 |
2026-02-26 |
Transgene |
Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell
|